Skip to main content
Premium Trial:

Request an Annual Quote

Australian Patent Office Upholds Two Benitec RNAi Patents

NEW YORK, Aug. 24 (GenomeWeb News) - The Australian Patent Office has reviewed and upheld two RNA interference patents held by Benitec, dealing Nucleonics' patent challenge a blow, Benitec said today.


Last year, Nucleonics asked the Commissioner of Patents in Australiato re-examine  Benitec's two RNAi patents, Australian Patent No. 743316 and Australian Innovation Patent No. 2001100608. Nucleonics filed the re-examination requests after being sued for patent infringement in the USby Benitec, which filed suit against Nucleonics and other companies in March of 2004. Both Australian patents were now upheld by the Australian Patent Office.


"In conjunction with the recent successful resolution of our contract dispute with Promega, this result will allow us to broadly license our issued patent estate and use any ensuing revenue to focus on developing RNA interference based therapeutics for the treatment of infectious diseases," said Benitec CEO Sara Cunningham in a statement.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.